In late August, Novavax also announced that its updated protein-based XBB COVID vaccine candidate retained neutralizing antibody responses to several emerging subvariants, including EG.5.1 and XBB.1.16.6. Unlike the mRNA-based boosters from Pfizer and Moderna, Novavax’s COVID vaccine would be the sole protein-based non-mRNA vaccine option available for the upcoming fall season.
The following visualization, based on CDC data, highlights the top SARS-CoV-2 variants for August and Sept…